Regulation of oligodendrocyte progenitor cell maturation by PPARδ: Effects on bone morphogenetic proteins

Maria Vittoria Simonini, Paul E. Polak, Anne I. Boullerne, Jeffrey Maurice Peters, Jill C. Richardson, Douglas L. Feinstein

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In EAE (experimental autoimmune encephalomyelitis), agonists of PPARs (peroxisome proliferator-activated receptors) provide clinical benefit and reduce damage. In contrast with PPARγ, agonists of PPARδ are more effective when given at later stages of EAE and increase myelin gene expression, suggesting effects on OL (oligodendrocyte) maturation. In the present study we examined effects of the PPARδ agonist GW0742 on OPCs (OL progenitor cells), and tested whether the effects involve modulation of BMPs (bone morphogenetic proteins). We show that effects of GW0742 are mediated through PPARδ since no amelioration of EAE clinical scores was observed in PPARδ-null mice. In OPCs derived from E13 mice (where E is embryonic day), GW0742, but not the PPARγ agonist pioglitazone, increased the number of myelin-producing OLs. This was due to activation of PPARδ since process formation was reduced in PPARδ-null compared with wild-type OPCs. In both OPCs and enriched astrocyte cultures, GW0742 increased noggin protein expression; however, noggin mRNA was only increased in astrocytes. In contrast, GW0742 reduced BMP2 and BMP4 mRNA levels in OPCs, with lesser effects in astrocytes. These findings demonstrate that PPARδ plays a role in OPC maturation, mediated, in part, by regulation of BMP and BMP antagonists.

Original languageEnglish (US)
Article numbere00025
Pages (from-to)1-13
Number of pages13
JournalASN Neuro
Volume2
Issue number1
DOIs
StatePublished - Mar 22 2010

Fingerprint

Bone Morphogenetic Proteins
Peroxisome Proliferator-Activated Receptors
Oligodendroglia
Stem Cells
Autoimmune Experimental Encephalomyelitis
Astrocytes
pioglitazone
Myelin Sheath
Messenger RNA
GW0742
Gene Expression

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Simonini, M. V., Polak, P. E., Boullerne, A. I., Peters, J. M., Richardson, J. C., & Feinstein, D. L. (2010). Regulation of oligodendrocyte progenitor cell maturation by PPARδ: Effects on bone morphogenetic proteins. ASN Neuro, 2(1), 1-13. [e00025]. https://doi.org/10.1042/AN20090033
Simonini, Maria Vittoria ; Polak, Paul E. ; Boullerne, Anne I. ; Peters, Jeffrey Maurice ; Richardson, Jill C. ; Feinstein, Douglas L. / Regulation of oligodendrocyte progenitor cell maturation by PPARδ : Effects on bone morphogenetic proteins. In: ASN Neuro. 2010 ; Vol. 2, No. 1. pp. 1-13.
@article{00d7e99b12c341b8a089d4375bf0a58c,
title = "Regulation of oligodendrocyte progenitor cell maturation by PPARδ: Effects on bone morphogenetic proteins",
abstract = "In EAE (experimental autoimmune encephalomyelitis), agonists of PPARs (peroxisome proliferator-activated receptors) provide clinical benefit and reduce damage. In contrast with PPARγ, agonists of PPARδ are more effective when given at later stages of EAE and increase myelin gene expression, suggesting effects on OL (oligodendrocyte) maturation. In the present study we examined effects of the PPARδ agonist GW0742 on OPCs (OL progenitor cells), and tested whether the effects involve modulation of BMPs (bone morphogenetic proteins). We show that effects of GW0742 are mediated through PPARδ since no amelioration of EAE clinical scores was observed in PPARδ-null mice. In OPCs derived from E13 mice (where E is embryonic day), GW0742, but not the PPARγ agonist pioglitazone, increased the number of myelin-producing OLs. This was due to activation of PPARδ since process formation was reduced in PPARδ-null compared with wild-type OPCs. In both OPCs and enriched astrocyte cultures, GW0742 increased noggin protein expression; however, noggin mRNA was only increased in astrocytes. In contrast, GW0742 reduced BMP2 and BMP4 mRNA levels in OPCs, with lesser effects in astrocytes. These findings demonstrate that PPARδ plays a role in OPC maturation, mediated, in part, by regulation of BMP and BMP antagonists.",
author = "Simonini, {Maria Vittoria} and Polak, {Paul E.} and Boullerne, {Anne I.} and Peters, {Jeffrey Maurice} and Richardson, {Jill C.} and Feinstein, {Douglas L.}",
year = "2010",
month = "3",
day = "22",
doi = "10.1042/AN20090033",
language = "English (US)",
volume = "2",
pages = "1--13",
journal = "ASN Neuro",
issn = "1759-0914",
publisher = "Portland Press Ltd.",
number = "1",

}

Simonini, MV, Polak, PE, Boullerne, AI, Peters, JM, Richardson, JC & Feinstein, DL 2010, 'Regulation of oligodendrocyte progenitor cell maturation by PPARδ: Effects on bone morphogenetic proteins', ASN Neuro, vol. 2, no. 1, e00025, pp. 1-13. https://doi.org/10.1042/AN20090033

Regulation of oligodendrocyte progenitor cell maturation by PPARδ : Effects on bone morphogenetic proteins. / Simonini, Maria Vittoria; Polak, Paul E.; Boullerne, Anne I.; Peters, Jeffrey Maurice; Richardson, Jill C.; Feinstein, Douglas L.

In: ASN Neuro, Vol. 2, No. 1, e00025, 22.03.2010, p. 1-13.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulation of oligodendrocyte progenitor cell maturation by PPARδ

T2 - Effects on bone morphogenetic proteins

AU - Simonini, Maria Vittoria

AU - Polak, Paul E.

AU - Boullerne, Anne I.

AU - Peters, Jeffrey Maurice

AU - Richardson, Jill C.

AU - Feinstein, Douglas L.

PY - 2010/3/22

Y1 - 2010/3/22

N2 - In EAE (experimental autoimmune encephalomyelitis), agonists of PPARs (peroxisome proliferator-activated receptors) provide clinical benefit and reduce damage. In contrast with PPARγ, agonists of PPARδ are more effective when given at later stages of EAE and increase myelin gene expression, suggesting effects on OL (oligodendrocyte) maturation. In the present study we examined effects of the PPARδ agonist GW0742 on OPCs (OL progenitor cells), and tested whether the effects involve modulation of BMPs (bone morphogenetic proteins). We show that effects of GW0742 are mediated through PPARδ since no amelioration of EAE clinical scores was observed in PPARδ-null mice. In OPCs derived from E13 mice (where E is embryonic day), GW0742, but not the PPARγ agonist pioglitazone, increased the number of myelin-producing OLs. This was due to activation of PPARδ since process formation was reduced in PPARδ-null compared with wild-type OPCs. In both OPCs and enriched astrocyte cultures, GW0742 increased noggin protein expression; however, noggin mRNA was only increased in astrocytes. In contrast, GW0742 reduced BMP2 and BMP4 mRNA levels in OPCs, with lesser effects in astrocytes. These findings demonstrate that PPARδ plays a role in OPC maturation, mediated, in part, by regulation of BMP and BMP antagonists.

AB - In EAE (experimental autoimmune encephalomyelitis), agonists of PPARs (peroxisome proliferator-activated receptors) provide clinical benefit and reduce damage. In contrast with PPARγ, agonists of PPARδ are more effective when given at later stages of EAE and increase myelin gene expression, suggesting effects on OL (oligodendrocyte) maturation. In the present study we examined effects of the PPARδ agonist GW0742 on OPCs (OL progenitor cells), and tested whether the effects involve modulation of BMPs (bone morphogenetic proteins). We show that effects of GW0742 are mediated through PPARδ since no amelioration of EAE clinical scores was observed in PPARδ-null mice. In OPCs derived from E13 mice (where E is embryonic day), GW0742, but not the PPARγ agonist pioglitazone, increased the number of myelin-producing OLs. This was due to activation of PPARδ since process formation was reduced in PPARδ-null compared with wild-type OPCs. In both OPCs and enriched astrocyte cultures, GW0742 increased noggin protein expression; however, noggin mRNA was only increased in astrocytes. In contrast, GW0742 reduced BMP2 and BMP4 mRNA levels in OPCs, with lesser effects in astrocytes. These findings demonstrate that PPARδ plays a role in OPC maturation, mediated, in part, by regulation of BMP and BMP antagonists.

UR - http://www.scopus.com/inward/record.url?scp=77953367307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953367307&partnerID=8YFLogxK

U2 - 10.1042/AN20090033

DO - 10.1042/AN20090033

M3 - Article

C2 - 20001953

AN - SCOPUS:77953367307

VL - 2

SP - 1

EP - 13

JO - ASN Neuro

JF - ASN Neuro

SN - 1759-0914

IS - 1

M1 - e00025

ER -